FibroBiologics Inc. FBLG
- Market cap
- $9.1M
- P/E
- 0.0×
Follow FBLG
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 21.56 | 4.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 1,100.00 | 46.70 |
High Price
|
|||
| — | — | — | — | — | — | 10 | 10 | 13 | 15 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | (2) | (5) | (16) | (11) | (19) |
EBT
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | (2) | (5) | (16) | (11) | (19) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 1 | 1 | 1 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (3.63) | (13.60) | (6.80) | (8.40) |
Earnings/Sh
|
|||
| — | — | — | — | — | 0.00 | (2.88) | (4.53) | (7.24) | (7.34) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | (0.35) | (0.11) | (0.12) |
Capex/Sh
|
|||
| — | — | — | — | — | 0.00 | (2.88) | (4.89) | (7.35) | (7.46) |
Free CF/Sh
|
|||
| — | — | — | — | — | 0.00 | (2.83) | 0.89 | 1.66 | 2.76 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 1 | 1 | 2 | 2 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | (1) | (4) | (6) | (12) | (16) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | (1) | (4) | (7) | (12) | (17) |
FCF
|
|||
| — | — | — | — | — | (1) | (4) | 0 | 2 | 5 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 9 | — |
Total Debt
|
|||
| — | — | — | — | — | 0 | (2) | (9) | (5) | (5) |
Net Debt
|
|||
| — | — | — | — | — | (1) | (4) | 1 | 3 | 6 |
Sh' Equity
|
|||
| — | — | — | — | — | 0.00% | (193.54%) | (228.99%) | (78.97%) | (143.08%) |
ROA
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | (824.53%) |
ROIC
|
|||
| — | — | — | — | — | 0.00% | 193.76% | 1,389.57% | (559.73%) | (419.44%) |
ROE
|
|||
FibroBiologics Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LGVN Longeveron Inc. | $9.1M | 0.0× | Compare |
| LNAI Lunai Bioworks Inc. | $8.8M | 0.0× | Compare |
| ALZN Alzamend Neuro, Inc. | $8.8M | 0.0× | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CSCIF COSCIENS Biopharma Inc. | $8.6M | 1.0× | Compare |
| IMRN IMMURON | $9.6M | 0.0× | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $9.7M | 0.0× | Compare |
| SNGX Soligenix Inc. | $8.4M | 0.0× | Compare |
FibroBiologics Inc. (FBLG) key facts
- FibroBiologics Inc. (FBLG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, FBLG traded at $1.39, a market capitalization of $9.1 million.
- Return on equity was −419.4% and debt-to-equity 0.00.
FibroBiologics Inc. (FBLG) Latest News
3 Sep
FibroBiologics Inc. obtains new U.S. patent for therapeutic use of fibroblasts in wound healing. Patent issuance adds to IP assets supporting wound healing programs without immediate revenue or product effects.
1 Sep
FibroBiologics Inc. (FBLG) received a new U.S. patent for treating degenerative disc disease using fibroblast conditioned media. Patent grant adds intellectual property protection for the company's fibroblast-based treatment approach.
27 Aug
FibroBiologics releases third batch of CYWC628 drug product for Phase 1/2 diabetic foot ulcer clinical trial. Batch release marks continued manufacturing support for ongoing Phase 1/2 trial.
FibroBiologics ships new drug to Australia to advance diabetic ulcer trial. Drug shipment marks trial progress that may moderately affect operations and sentiment without major trajectory shift.
20 Aug
FibroBiologics gains acceptance for its Australian patent on cannabidiol adjuvant therapy for degenerative disc disease. Australian patent acceptance strengthens FibroBiologics intellectual property for a core therapy without immediate broad market effects.
18 Aug
FibroBiologics announces chondrocyte spheroids demonstrated cartilage repair in a preclinical study of degenerative joints. Preclinical cartilage repair data may moderately advance FibroBiologics product pipeline in joint diseases.
11 Aug
FibroBiologics Inc. received a U.S. patent for using fibroblasts to enhance survival and function of transplanted insulin-producing islets. Patent grant secures key intellectual property for fibroblast-based islet transplantation technology.
5 Aug
FibroBiologics Inc. received a European patent covering gene therapy for cartilage regeneration. European patent grant strengthens FibroBiologics intellectual property in cartilage regeneration therapy.
31 Jul
FibroBiologics reported second quarter 2026 financial results and advanced its clinical trial for the lead wound care candidate. Progress on the lead clinical trial may moderately affect future performance and market position.
7 Jul
FibroBiologics completes manufacturing of third CYWC628 batch for Phase 1/2 diabetic foot ulcer trial. Batch production marks incremental progress on lead candidate toward clinical testing.
29 Jun
FibroBiologics Inc. closed a private placement of up to $9.0 million priced at-the-market under Nasdaq rules. The $9 million private placement provides additional capital that supports operations without altering the company's long-term trajectory.
26 Jun
FibroBiologics Inc. (FBLG) announces up to $9.0 million private placement priced at-the-market under Nasdaq rules. Private placement raises up to $9 million in capital to support company operations.
22 Jun
FibroBiologics receives U.S. notice of allowance for patent covering topical fibroblast spheroid therapy for wound healing. Patent allowance advances IP protection for core fibroblast-based wound therapy.
16 Jun
FibroBiologics advances patient dosing in Phase 1/2 trial of CYWC628 for diabetic foot ulcers. Phase 1/2 dosing start for CYWC628 marks pipeline progress for FibroBiologics.
4 Jun
FibroBiologics Inc. has initiated a Phase 1/2 clinical trial of CYWC628. Phase 1/2 trial start marks major pipeline progress that can shift company trajectory and investor sentiment.
3 Jun
FibroBiologics dosed first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers. Dosing first patients advances early-stage product development for FibroBiologics.
FibroBiologics has dosed the first patients in its diabetic foot ulcers clinical trial. Dosing first patients marks incremental clinical progress with moderate effects on development timeline and sentiment.
2 Jun
FibroBiologics Inc. (FBLG) explores potential breakthrough psoriasis treatment using CYPS317 data. CYPS317 data could drive major shifts in FBLG's psoriasis pipeline and market trajectory.
18 May
FibroBiologics files patent application for oral administration of fibroblast therapeutics. Patent filing advances potential oral delivery methods for fibroblast-based treatments.
11 May
FibroBiologics Inc. (FBLG) is advancing development of a fibroblast-based treatment for Hantavirus, a rare but potentially deadly infectious disease. Pipeline expansion into Hantavirus treatment via fibroblast technology bolsters FBLG's innovation profile but remains early-stage without guaranteed clinical success.
5 May
FibroBiologics Inc. (FBLG) CEO issued a letter to shareholders outlining company progress, clinical trial advancements, financial position, and strategic plans for future growth. CEO letter provides updates on clinical progress and strategy, offering moderate influence on investor sentiment and operational outlook.
4 May
FibroBiologics reports preclinical data showing fibroblast spheroids actively reprogram the burn wound environment to drive healing and reduce scarring. Preclinical data on fibroblast spheroids reprogramming burn wounds for enhanced healing and reduced scarring represents a significant advancement in FBLG's core regenerative medicine pipeline, potentially boosting investor sentiment and future clinical development.
FibroBiologics Inc. (FBLG) announces release of CYWC628 drug product for Phase 1/2 clinical trial targeting diabetic foot ulcers. Releasing CYWC628 for Phase 1/2 trial advances key clinical pipeline milestone with potential to boost investor sentiment and market performance.
30 Apr
FibroBiologics Inc. (FBLG) reported Q1 2026 financial results and provided a corporate update. Quarterly financial results and corporate update affect financial performance and investor sentiment.
10 Apr
FibroBiologics presented its novel Thymus Organoid Platform at the Keystone Symposia on Aging and Immunity to combat age-related immune decline. Presentation of innovative thymus organoid platform at prestigious Keystone Symposia underscores FibroBiologics' advancement in regenerative immunology for aging, poised to significantly elevate investor sentiment and competitive positioning.
2 Apr
FibroBiologics Inc. (FBLG) closed a $3 million public offering, securing funds through the issuance and sale of common stock and warrants. Closing a $3 million public offering provides moderate financial support for operations and development but is limited in scale relative to broader biotech funding needs.
1 Apr
FibroBiologics Inc. (FBLG) advances fibroblast therapy on multiple fronts, highlighting progress in clinical trials, manufacturing, and partnerships. Advancements across multiple fronts in core fibroblast therapy represent major strategic moves likely to boost FBLG's trajectory and investor sentiment.
31 Mar
FibroBiologics Inc. (FBLG) announces successful manufacturing of CYWC628 drug product to support upcoming diabetic foot ulcer clinical trial. Successful manufacturing of CYWC628 enables advancement to diabetic foot ulcer clinical trial, marking a major pipeline milestone with potential to boost investor sentiment and competitive positioning.
FibroBiologics Inc. (FBLG) priced a $3 million public offering of common stock and warrants. $3 million public offering provides moderate capital to bolster short-term financial position without major strategic shifts.
12 Mar
FibroBiologics Inc. (FBLG) announces advances in burn treatment using proprietary fibroblast spheroid technology. Advances in proprietary fibroblast spheroid technology for burn treatment mark a significant milestone in FBLG's core biotech pipeline, poised to enhance competitive positioning and investor sentiment.